Table 1. Outcomes of selected salvage... | American Society of Hematology

Table 1.

Outcomes of selected salvage therapy programs

Regimen	N	Rel	Primary ref	CR-PET neg pre-AHCT, %	CD34⁺ cells/kg collected, × 10⁶	AHCT, %	PFS ITT
BV → sequential ICE²⁹	66	33	33	73	6.2	95	79% at 3 y
BV → sequential salvage therapy³⁰	37	13	24	73	5.6	89	72% at 1.5 y
BV-ESHAP³²	66	26	40	70	5.75	92	NA
Benda-BV³⁴	54	27	27	74	4	74	63% at 2 y
BV-ICE³¹	16	5	11	69	11	75	NA
BV-DHAP³³	12	10	2	90	5.3	100	NA
BV-Nivo³⁵	62	34	28	64	4.7	46	NA
ICE/GVD⁷⁹	97	56	41	76	6.3	88	68% at 8 y
BeGV³⁶	59	27	32	73	8.8	73	63% at 2 y
ICE⁸⁰	65	45	20	26*	7	85	58% at 2 y
DHAP⁸¹	102	86	16	21*	6.1	NA	NA
GVD³⁷	51	NA	NA	20*	NA	76	52% at 4 y

Regimen	N	Rel	Primary ref	CR-PET neg pre-AHCT, %	CD34⁺ cells/kg collected, × 10⁶	AHCT, %	PFS ITT
BV → sequential ICE²⁹	66	33	33	73	6.2	95	79% at 3 y
BV → sequential salvage therapy³⁰	37	13	24	73	5.6	89	72% at 1.5 y
BV-ESHAP³²	66	26	40	70	5.75	92	NA
Benda-BV³⁴	54	27	27	74	4	74	63% at 2 y
BV-ICE³¹	16	5	11	69	11	75	NA
BV-DHAP³³	12	10	2	90	5.3	100	NA
BV-Nivo³⁵	62	34	28	64	4.7	46	NA
ICE/GVD⁷⁹	97	56	41	76	6.3	88	68% at 8 y
BeGV³⁶	59	27	32	73	8.8	73	63% at 2 y
ICE⁸⁰	65	45	20	26*	7	85	58% at 2 y
DHAP⁸¹	102	86	16	21*	6.1	NA	NA
GVD³⁷	51	NA	NA	20*	NA	76	52% at 4 y

BeGV, bendamustine, gemcitabine, vinorelbine; Benda, bendamustine; NA, not yet available; Nivo, nivolumab; ref, refractory; rel, relapsed.

Computed tomography criteria (no functional imaging included because of study timeframe).